Third-Party Requests for University Information Frequently Asked Questions Document

There are instances when faculty and staff are approached, either in person or through document requests such as warrants or subpoenas, by law enforcement agencies, other investigative agencies, the media, or outside legal counsel regarding University-related matters. The attached fact sheet contains information to help faculty and staff handle these encounters appropriately and to comply with applicable laws, such as privacy laws, including but not limited to, the Family Educational Rights and Privacy Act (“FERPA”) and the Health Insurance Portability and Accountability Act (“HIPAA”).  Please see the attached Word file “Government Agent FAQ” or click here for more information.

 

Final NIH Policy for Data Management and Sharing Plan - REQUIRED

This is a reminder that this policy became effective January 25, 2023 for all NIH applications, unless specified otherwise in the RFA.
Please go to https://grants.nih.gov/grants/guide/notice-files/NOT-OD-21-013.html for the Final Policy Announcement and guidelines.
Please see the DMS Plan Format document attached.

 

Resignation of Stanford’s President - Reminder of Research Integrity Responsibilities for all Principal Investigators.

Following a highly publicized investigation into data manipulation in several published papers, the renowned neuroscientist, Dr. Marc Tessier-Lavigne, has recently announced his resignation as President of Stanford University. Reports state that although Dr. Tessier-Lavigne was not directly responsible for the data falsification and manipulation in the papers (others in his lab were), the investigative committee pointed out that as Principal Investigator (PI) and Corresponding Author he failed to “decisively and forthrightly” correct or retract the problematic publications once he became aware of the issues. Principal Investigators have the ultimate responsibility to carefully verify the authenticity, rigor and reproducibility of all data produced in their lab – especially when the data is reported out in scholarly activities like publications, presentations, and grant applications. Failure to adhere to this important responsibility can cause serious career-limiting/ending consequences for researchers – including PIs who have supervisory responsibility over trainees and staff who choose to engage in scholarly and research misconduct such as data falsification, data fabrication, and plagiarism. All researchers must stay vigilant and dedicate the time needed to ensure research excellence. The Office of the VPR would like to remind all PIs on our campus that best practices should always be followed in their respective laboratories and it is of the utmost importance for all PIs to ensure they match all data and/or processed images with the raw data as figures and tables for manuscripts, posters, presentations, and grant applications are being generated. 

Read more about this research integrity investigation and outcome at the following link from the journal Science: https://www.science.org/content/article/stanford-president-to-step-down-despite-probe-exonerating-him-of-research-misconduct

 

Clinical Scientist Working Group

Mary Beth Humphrey, MD, PhD, Associate Dean for Research for the College of Medicine, hosts a monthly forum for research questions and answers, updates on processes, networking with other faculty, and general science discussions.  The meetings will be the fourth Thursday of each month (August 2023- January 2024 then the 4^th Tuesday of the month from February 2024- July 2024) from 5:15- 6:30 PM.  We will also have the pleasure of Dr. Stephan Ladisch joining these calls.  Dr. Ladisch has successfully mentored many OUHSC faculty to obtain K08 and NIH grants. PHF has sponsored his services to mentor more faculty in this capacity.  The External Mentoring and Grant Development Program was established with the goal of enhancing the research development of junior faculty and ultimately optimizing their possibilities for obtaining external (national) research support.  Dr. Ladisch is available to help refine specific aims pages, formulate clear aims for new grants, and to help revise applications. Send inquiries about grant help to Marybeth-humphrey@ouhsc.edu or SLADISCH@childrensnational.org.

Meeting Dates
August 24, 2023
September 8, 2023
October 26, 2023
November 23, 2023* May be rescheduled due to holiday
December 28, 2023
January 25, 2024
February 27, 2024
March 26, 2024
April 23, 2024
May 28, 2024
June 25, 2024
July 23, 2024

Join Zoom Meeting
https://zoom.us/j/93857869472?pwd=Mk1EUmlFNTl4cWdJWkU3QzBuNk9lUT09
Meeting ID: 938 5786 9472
Passcode: 58192553

 

2023 OSCTR Pilot Grants Program

Description: The Oklahoma Clinical and Translational Science Institute (OCTSI) and Oklahoma Shared Clinical and Translational Resources (OSCTR) is soliciting applications for its Clinical and Translational Research Pilot (CTRP) Grants Program. The purpose of the program is to provide funding for clinical and translational pilot projects from investigators of the OSCTR member institutions and preference is given to investigators who qualify as NIH New or Early Stage Investigators, or to investigators who are transitioning to clinical and translational research. The program seeks to support proposals designed to generate preliminary data that will result in improved health and/or health outcomes for citizens of Oklahoma and other IDeA states and enhance the competitiveness of the investigator for future extramural funding. The program also seeks to fund innovative concepts, approaches, and methodologies that bring fresh new ideas to solving the health issues of those living in Oklahoma and collaborating IDeA states. Projects that focus on the medically underserved and on health concerns prevalent within Oklahoma and our OSCTR partners will be a priority. Only projects which meet the NIH definition of clinical and/or translational research will be accepted.
The forms, instructions, and submission link can be found at:  http://osctr.ouhsc.edu/pilots2023. Deadline: Friday, September 15, 2023 at 5:00 PM CDT. If you have any technical questions about the grant submission process or grant eligibility please contact the OSCTR Research Navigator Service at osctr@ouhsc.edu or call 405-271-3480.

 

Investigator Initiated Trials Funding Committee (IITFC), Clinical Trials Office-Protocol Support Unit

Description: Grant proposals are being accepted for the 2023 Fall cycle from Stephenson Cancer Center Providers for their investigator-initiated clinical trials (IITs) or translational work for the amount of up to $100,000 for clinical trials, and up to $25,000 for translation research. All applications should be submitted to the Protocol Support Unit at SCC-IIT-Office@ouhsc.edu and should adhere to the Grant template and Submission Checklist provided with this notice. Investigators should request the budget template from the CTO Budget Manager (ClinicalTrialBudgets@ouhsc.edu). 
Deadline: October 9^th, 2023 at 5 pm CST
Link to the full announcement or a flier: Please refer to the attached flyer for additional funding criteria and details.

 

Once-a-year NIH SBIR Contract Solicitation from NIH (PHS-2024-1)

Any OUHSC researcher interested in commercializing their research should look at this once-a-year solicitation.  It relates to one of the following specific areas listed below. The once-a-year NIH SBIR Contract Solicitation will soon be coming out and from prior experience of other investigators it is often the single easiest SBIR award mechanism to get a fundable score. This is not the normal, more academic NIH SBIR, the contract proposals don’t go through the Center for Scientific Review (CSR).  The awards directly fund what NIH program managers want to fund. So if, you are interested in launching a startup, securing SBIR funding, and there is a topic in the list below that matches your area of interest, this could be a great opportunity. If any faculty are interested they can contact John Hanak (jhanak@ou.edu), the Chief Innovation and Corporate officer that oversees these activities on the OUHSC, OU-Norman, and OU-Tulsa campuses. He will be able to get you in touch with the OK Catalyst team and they will help you through the process.  

THE FOLLOWING RESEARCH TOPICS ARE ANTICIPATED TO BE INCLUDED IN SBIR CONTRACT SOLICITATION PHS-2024-1
NATIONAL INSTITUTES OF HEALTH (NIH)
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES (NCATS):
Topic 024 - Small Manufacturing Systems to Produce Research Grade Pharmaceutical Intermediates
NATIONAL CANCER INSTITUTE (NCI):
Topic 455 - Point-of-Care Detection of Prostate Specific Antigen
Topic 456 - Rapid and Affordable Point-of-Care HPV Diagnostics for Cervical Cancer Control
Topic 457 - Technologies for Detecting Tumor-Derived Cell Clusters
Topic 458 - Microbiome-Based Tests for Cancer Research, Diagnosis, Prognosis and/or Patient Management
Topic 459 - Automated Software for Point-of-Care Testing to Identify Cancer-Associated Malnutrition
Topic 460 - Evaluation Datasets as Medical Device Development Tools for Testing Cancer Technologies
Topic 461 - Ultra-Fast Dose Rate (FLASH) Radiation Detectors and Safety Systems for Cancer Treatment
Topic 462 - Organ-on-Chip for Preclinical and Translational Radiobiological Studies
Topic 463 - Translation of Novel Cancer-specific Imaging Agents and Techniques to Mediate Successful Image-guided Cancer Interventions
Topic 464 - Cloud-Based Multimodal Data Analysis Software for the Cancer Research Data Commons
Topic 465 - Cancer Prevention and Treatment Clinical Trials Tools for Recruitment and Retention of Diverse Populations
NATIONAL INSTITUTE ON AGING (NIA): 
Topic 010 - Technology to facilitate characterization of the exosome in under –resourced populations for AD/ADRD Studies
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID):
Topic 124 - Development of Next-Generation Devices and Materials-Based Platforms for the Administration of HIV-1 Broadly Neutralizing Antibodies
Topic 125 - Development of Long-Acting Treatments for HCV Cure
Topic 126 - Rapid Diagnostic Assays for Self-Monitoring of Acute or Rebound HIV-1 Infection
Topic 127 - Multiplexed Patient Administered Diagnostics for Hepatitis B, Hepatitis C, and HIV
Topic 128 - Adjuvant Development for Vaccines for Infectious and Immune-Mediated Diseases
Topic 129 - Reagents for Immunologic Analysis of Non-mammalian and Underrepresented Mammalian Models
Topic 130 - Adjuvant Discovery and Down-Selection for Vaccines against Infectious and Immune-Mediated Diseases
Topic 131 - Development of Bacteriophage for Treatment of Mycobacterial Infections
Topic 132 - Novel Diagnostic Biomarker Discovery and Validation for Malaria and Select Neglected Tropical Diseases (NTDs)
Topic 133 - Development of a Serological Test for Herpes Simplex Types 1 and 2 Infections
Topic 134 - Alternatives to Benzathine Penicillin for Treatment of Syphilis
Topic 135 - Software or Web Services to Automate Metadata Enrichment and Standardization for Data on Infectious and Immune – Mediated Diseases
Topic 136 - Software or Web Services to Re-Represent Existing Scientific Data and Knowledge into a Knowledge Graph Format
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (NHLBI):
Topic 115 - Clinical Instrument for Para-Hydrogen (pH2) Based Signal Amplification by Reversible Exchange (SABRE) for Hyperpolarizing 13C-Pyruvate and Other Probes for MRI Imaging
NATIONAL INSTITUTE OF MENTAL HEALTH (NIMH):
Topic 001 - Point-of-Care HIV Viral Load and Drug Adherence Assays
Topic 002 - Development of novel In-vitro and In-vivo Models to support NeuroHIV Research

 

Office of Technology Commercialization presents the following opportunity for researchers to engage with industry (click here for more information, or email otc@ou.edu or gina-mcmillen@ouhsc.edu).  

• A pharmaceutical company focused on women’s health is seeking novel druggable targets and drug candidates in the area of obstetrics and gynecology for in-licensing or early collaboration, including research project/PhD funding.  All mechanisms of action are of interest with examples being anti-fibrotic effect, ovulation failure, hormone replacement and osteoporosis. Open to different modalities with small molecule and peptides of highest interest.  Novel screening methods to identify targets and research related to novel contraceptives are also of interest.  Submission entails a one-page 200-300 word non-confidential brief. (deadline 08/19). 
• Procter & Gamble is seeking synthetic biology expertise and approaches for production of platform chemicals, surfactants, chelants, polymers and perfume raw materials and enzymes for use in the fabric, home care and beauty industries. Open to any novel and scalable synthetic biology approaches that can be applied to make production processes more sustainable and cost-effective; specific interest in C1/C2 chemistry (platform chemicals) and long chain C-12-14 nd C16-18 chemistry (e.g. long chain fatty acids/alcohols and oils. Submission entails a one-page 200-300 word non-confidential brief. (deadline 08/19). 
• A worldwide manufacturing company is seeking alternative chemistries to liquid PFAS, specifically PFPE, PFAE and fluorosilicones.  Ideally these chemicals will be sustainable, cost-effective and high-performance alternatives.  Key performance features include lubricity, wide temperature performance, oxidative stability, anti-wear and material compatibility.  Solid lubricants are out of scope.  Submission entails a one-page 200-300 word non-confidential brief. (deadline 08/25). 
• Bicycle Therapeutics is seeking proposals to enhance understanding how their novel compound library, which are constrained bicycle peptides, interact with OX40 in disease, including but not limited to cancer and immune-inflammation.  Initial priority is proposals focused on in vitro biology with potential to expand to in vivo.  Also interested in research that reveals new insights to understand their MOA.  Submission completion of the application form, with a non-confidential overview of your proposal. (deadline 09/01). 

NOTE: If the project is selected to move forward with a full application, it will need to be routed through SoonerTrack II.

 

• Notice of Intent to Publish Funding Opportunity Announcements to Understand and Improve Diagnostic Safety in Ambulatory Care
  (NOT-HS-23-018)
• Notice of Request for Letters of Interest: NIAAA Alcohol Pharmacotherapy Evaluation Program (APEP)
  (NOT-AA-23-016)
• Notice of Pre-application Webinar for RFA-CA-23-036: Mechanisms of Fusion-Driven Oncogenesis in Childhood Cancers; U01 Clinical Trials Not Allowed and RFA-CA-23-037: Next Generation Chemistry Centers for Fusion Oncoproteins; UM1 Clinical Trial Not Allowed
  (NOT-CA-23-080)
• Notice of NLM Withdrawal of Participation from PAR-21-277 Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Institutionally-Focused Research Education Award to Promote Diversity (UE5 - Clinical Trial Not Allowed)
  (NOT-LM-23-004)
• Notice of Information: High-Priority Principles of Rigorous Research for the Final Receipt Date of NINDS Materials to Enhance Training in Experimental Rigor (METER) Funding Opportunity
  (NOT-NS-23-101)
• Notice of Participation of NIBIB in "RFA-NS-22-025 HEAL Initiative Advanced Postdoctoral-to-Independent Career Transition Award in PAIN and SUD Research to Promote Diversity (K99/R00 Independent Clinical Trial Not Allowed)"
  (NOT-EB-23-013)
• Notice of Participation of NIBIB in "RFA-NS-22-022 HEAL Initiative Advanced Postdoctoral-to-Independent Career Transition Award in PAIN and SUD Research (K99/R00 Independent Clinical Trial Not Allowed)"
  (NOT-EB-23-015)
• Notice of Change to Key Dates for RFA-HG-23-024: Limited Competition: High Quality Reference Genomes (UM1 Clinical Trial Not Allowed) and RFA-HG-23-025: Limited Competition: Human Pangenome Coordinating Center (U41) Clinical Trial Not Allowed
  (NOT-HG-23-047)
• Notice of Correction to Application Instructions for RFA-HL-24-007 Single Source: Molecular Atlas of Lung Development Program (LungMAP) Phase 3 - Data Coordinating Center (U24- Clinical Trial Not Allowed)
  (NOT-HL-23-103)
• Notice of Change to Application Instructions for RFA-HL-24-012 Single Source: Molecular Atlas of Lung Development Program (LungMAP) Phase 3 - Human Tissue Core (U01- Clinical Trial Not Allowed)
  (NOT-HL-23-104)
• Notice of Correction to Application Project Period in RFA-MD-23-003, "Innovations for Healthy Living - Improving Minority Health and Eliminating Health Disparities (R43/R44 - Clinical Trial Optional)"
  (NOT-MD-23-012)
• Notice of Change to Extend Last Receipt Date for PAR-21-032: "NINDS Ruth L. Kirschstein National Research Service Award (NRSA) for Training of Postdoctoral Fellows (F32 Clinical Trial Not Allowed)"
  (NOT-NS-23-098)
• Notice of Correction to Budget Form and Budget Instructions for RFA-RM-23-004 "NIH Directors Pioneer Award Program (DP1 Clinical Trial Optional)"
  (NOT-RM-23-021)
• Notice of Correction to Award Budget in RFA-RM-23-013 "Partnerships with Common Fund Data Ecosystem Resources (U24 Clinical Trial not Allowed)"
  (NOT-RM-23-022)
• Notice of Intent to Publish a Funding Opportunity Announcement for Limited Competition: The Harmonized Cognitive Assessment Protocol (HCAP) Network (U24 Clinical Trial Not Allowed)
  (NOT-AG-23-045)
• Notice of Special Interest (NOSI): BRAIN Initiative: Mentored Clinician Scientist Research Career Development program to Develop Expertise in Intracranial Human Neuroscience Research (K08)
  (NOT-AA-23-015)
• Notice of Special Interest (NOSI): Understanding Immune Evasion in Tickborne Diseases
  (NOT-AI-23-053)
• Notice of Special Interest (NOSI): Research on Early Allergy Determinants using Biosamples from the SUNBEAM Birth Cohort
  (NOT-AI-23-058)
• Notice of Special Interest (NOSI): Pragmatic Trials in Low Resource Settings
  (NOT-CA-23-078)
• Notice of Special Interest (NOSI): Small Business Initiatives for Innovative tools and Technologies for Improving Outcomes for Maternal Health
  (NOT-EB-23-005)
• Notice of Special Interest (NOSI): Lymphatic System in Health and Disease (R01)
  (NOT-HL-23-099)
• Notice of Special Interest (NOSI): Addressing Organizational Factors to Prevent or Mitigate Nurse Burnout
  (NOT-NR-23-012)
  National Institute of Nursing Research

 

NOTE: When only one application is allowed per Institution according to the sponsor instructions, a one-page letter of intent summarizing the proposed project should be submitted to the Vice President for Research at least two months prior to the application deadline (unless otherwise noted).  The letters of intent will be reviewed and a single application will be chosen for submission from the University.

 

• Pharmacokinetic and Pharmacodynamic (PK/PD) Studies of mTOR Inhibitors on Aging-Related Indications (U01 Clinical Trial Required)
  (RFA-AG-24-044)
  Application Receipt Date(s): November 07, 2023
• Role of Environmental Stress in the Health Inequities of Alzheimer's Disease-Related Dementias (ADRD) (R01 - Clinical Trial Not Allowed)
  (RFA-NS-24-024)
  Application Receipt Date(s): November 01, 2023
• Public Health Communication Messaging about the Continuum of Risk for Tobacco Products (U01 Clinical Trial Required)
  (RFA-OD-23-021)
  Application Receipt Date(s): December 06, 2023
• Pilot Projects Enhancing Utility and Usage of Common Fund Data Sets (R03 Clinical Trial Not Allowed)
  (RFA-RM-23-015)
  Application Receipt Date(s): November 17, 2023

 

New ARPA-H Program to Fund Novel Technologies for More Precise Cancer Tumor Removal

ARPA-H’s new Precision Surgical Interventions (PSI) program aims to deliver groundbreaking tools to enable surgeons to successfully remove cancer from patients through a single operation by better identifying and differentiating between healthy and cancer tissue. Through a Broad Agency Announcement (BAA) for the PSI program, ARPA-H will solicit proposals for strategies to improve visibility of cancer and other critical anatomical structures during surgery.
“With the Precision Surgical Interventions program, we're seeking to fundamentally change how surgery is done. Imagine if surgeries fixed problems flawlessly, the first time,” said Ileana Hancu, Ph.D., ARPA-H PSI Program Manager. "Cancer is one disease we're addressing, but the potential benefits of the tools developed could extend across many types of surgery, for many diseases and populations."
Read the news announcement and learn more about PSI on its program page.

 

The National Cancer Institute (NCI): Informatics Technology for Cancer Research (ITCR)

Description: The ITCR program has funding opportunities aimed at successive stages of informatics technology development, including:

• Innovative Algorithm Development,
• Prototyping and Hardening,
• Advanced Development and Enhancement, and
• Sustainment of Tools.

Next receipt date is November 17, 2023.

Contact Dr. Juli Klemm with questions at juli.klemm@nih.gov.

 

The National Cancer Institute (NCI): Innovative Molecular Analysis Technologies (IMAT)

Description: The IMAT program has funding opportunities to support the development of technologies suitable for the molecular and cellular targeting or analysis of cancers and their host environment in support of basic, clinical, and epidemiological research:

• Early-stage innovative molecular and cellular analysis technologies
• Advanced development and validation of emerging technologies

IMAT also supports the development of novel technologies for sample collection, processing, and preservation:

• Early-stage innovative biospecimen science technologies
• Advanced development & validation of biospecimen science technologies

Incorporate new technologies into your ongoing research.

NCI offers supplemental funding for current NCI grantees to incorporate new technologies developed through the IMAT program into their ongoing research. Applications should offer to accelerate the research and may increase the scope of the projects in addition to promoting collaborations and independent validation of these technologies. Check out the list of IMAT projects to find new technologies that could advance your research!

Next receipt date is September 1, 2023.

Contact Dr. Kelly Crotty or Dr. Tony Dickherber with questions at kelly.crotty@nih.gov or anthony.dickherber@nih.gov.

 

NOT-CA-22-083: NCI has issued a Notice of Special Interest to support the development of technologies and informatics tools specifically for metabolomics and lipidomics research in cancer.

NOT-CA-23-037: NCI has issued a Notice of Special Interest to support the development of technologies and informatics tools specifically for research in cancer control and population sciences.

 

Advanced Research Projects Agency for Health (ARPA-H) Open Broad Agency Announcement (BAA)

Description: The mission of ARPA-H is to accelerate better health outcomes for everyone by supporting the development of high-impact solutions to society's most challenging health problems. Awardees will develop groundbreaking new ways to tackle health-related challenges through highpotential, high-impact biomedical and health research. With a scope spanning the molecular to the societal, ARPA-H seeks proposals that aim to rapidly achieve better health outcomes across patient populations, communities, diseases, and health conditions, including in support of the Cancer Moonshot. Proposals are expected to use innovative approaches to enable revolutionary advances in science, technology, or systems.

Abstract deadline: March 14, 2024

Link to Full Announcement: https://sam.gov/opp/caf109b75a0449418ead3630cef1915e/view#general

 

International Center for Responsible Gaming (ICRG) Apply for Funding for Research on Gambling Disorder and Responsible Gambling

• Research on Lottery Gambling (up to $40,000), Deadline: Sept. 1, 2023
• Research on Gambling Advertising (up to $172,500), Deadline Sept. 15, 2023
• Research on Online Gambling and Potential Harms (up to $172,500) , Deadline: Sept. 29, 2023
• Research on Responsible Gambling/Prevention of Gambling Disorder (up to $207,000), Deadline Oct. 16, 2023

For more information and to download the grants announcement and application form, visit https://www.icrg.org/information/apply-for-icrg-funding

 

The Robert Wood Johnson Foundation’s (RWJF): Health Data for Action (Data Access Award)

Description: Access to rich data is a cornerstone of producing timely and objective research. Data can build evidence that leads to a fair and just opportunity for health, for all.  A new call for proposals offers no-cost access to timely, relevant, inclusive data that inform policy to make healthcare more affordable and equitable.  Health Data for Action will award successful applicants with access to data sets to support innovative research that answers important research questions and inform health policy. Data include electronic health record and clinical data; claims and encounter data; and transparency in coverage data. First-time principal investigators will receive funding up to $100,000 per project.

Applications Deadline: August 18, 2023

Link to Full Announcement: https://www.rwjf.org/en/grants/active-funding-opportunities/2023/health-data-for-action-data-access-award.html?rid=0032S00002ZyzqpQAB&et_cid=2196580